Sci Trans Med:人工血管替代物试验成功,人类或结束肾病透析!

2017-11-02 sunshine2015 来宝网

明尼苏达大学的研究人员创建了一个新的实验室生长的血管替代物,其完全由生物材料组成,但令人惊讶的是在植入时不含任何活细胞。可以用作肾透析患者的“现成”移植物的血管,在最近的非人灵长类动物研究中表现良好。

新的组织-工程血管替代物进一步接近人体试验】明尼苏达大学的研究人员创建了一个新的实验室生长的血管替代物,其完全由生物材料组成,但令人惊讶的是在植入时不含任何活细胞。可以用作肾透析患者的“现成”移植物的血管,在最近的非人灵长类动物研究中表现良好

它是第一个非合成的,脱细胞的移植物,当植入时,被接受者自己的细胞重新填充细胞。这一发现每年可以帮助成千上万的肾透析患者。移植物也可以在未来适应用作冠状和周边旁血管和管状心脏瓣膜。

该研究今天发表作为科学转化医学的封面故事。明尼苏达大学也授权该技术。

根据美国肾脏数据系统年度数据报告,美国每年有超过10万人每年开始进行血液透析治疗肾脏疾病,全国有超过40万人正在接受挽救生命的血液透析治疗。动静脉瘘将动脉连接到手臂的静脉,目前是血液透析血管通路的首选方式。然而,30-50%的患者出现并发症,需要使用称为动静脉移植物的人造管连接静脉和动脉。

目前,这些人工移植物由容易发生凝血,感染等并发症的合成材料制成。在实验室中从细胞和生物材料生长的移植物可能导致较少的不良反应,但活组织对于长期储存不稳定,并且可以诱导免疫应答,除非使用患者自身的细胞,这两者都是商业化和临床使用的障碍。

在这项临床前研究中,明尼苏达大学的研究人员在实验室中从产后人类皮肤细胞中产生了血管样管,该细胞嵌入由凝血状材料制成,该纤维蛋白参与血液凝固。研究人员将细胞凝集的凝胶置于生物反应器中,并使管长达七周,然后在最后一周洗去细胞。剩下的是胶原蛋白和细胞分泌的其他蛋白质,形成一种全天然但非生命的植入管。

明尼苏达大学生物医学工程系教授罗伯特·托兰奇洛(Robert Tranquillo)领导研究,他说:“我们利用身体正常的伤口愈合系统,从纤维蛋白凝胶中的皮肤细胞开始,这是自然愈合的起点。 “在最后一步洗掉细胞会减少排斥的机会,这也意味着植入物该只在需要时可以被储存和植入,因为它们不再是生物材料,今后,成千上万的实验室生长的植入物只可以由一个供体的小皮肤活组织检查制成,然后存放在架子上,以供患者使用。

为了测试血管,研究人员将15厘米长(约5英寸)的实验室生长的移植物植入Mayo Clinic捐赠的成年狒狒,因为它正在关闭其灵长类动物设施。植入后6个月,移植物出现像血管一样的现象,研究人员观察到收集者在管壁内居住的健康细胞。没有移植物钙化,只有一个破裂,这是由于无意的机械损伤与处理。六个月后的移植物被证明可承受几乎平均人血压的30倍而没有爆裂。植入物没有显示出免疫反应并抵抗感染。此外,移植物通过自我修复来抵抗重复的针刺,这对于进行长期透析的患者来说是必要的过程。

“这项临床前临床试验对我们非常重要,”Tranquillo说。 “在以前的研究中,我们将血管植入到羊中,但是我们需要在冒着生命危险的前提下,以较为人性化的模型进行测试,因为我们的材料的成功取决于受体将其收集到没有免疫的活组织中的能力,尽管它成功地在一只羊身上实现了,但人类的反应可能已经失败了。”

随着这项研究的成功,Tranquillo和该团队将寻求FDA批准儿科心脏缺陷儿童的临床试验,因为他们最近报道了一项关于自然通讯的研究,这种材料也有能力发展。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739802, encodeId=bb491e39802de, content=<a href='/topic/show?id=c318248e2f8' target=_blank style='color:#2F92EE;'>#人工血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24872, encryptionId=c318248e2f8, topicName=人工血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb434562879, createdName=thinkibmz_44722605, createdTime=Sat Jan 06 09:49:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656901, encodeId=659f165690168, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue May 22 15:49:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608197, encodeId=176d160819e00, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 04 07:49:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258317, encodeId=c3a825831ee9, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 03 10:50:38 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258112, encodeId=558925811266, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Nov 02 19:24:43 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739802, encodeId=bb491e39802de, content=<a href='/topic/show?id=c318248e2f8' target=_blank style='color:#2F92EE;'>#人工血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24872, encryptionId=c318248e2f8, topicName=人工血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb434562879, createdName=thinkibmz_44722605, createdTime=Sat Jan 06 09:49:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656901, encodeId=659f165690168, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue May 22 15:49:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608197, encodeId=176d160819e00, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 04 07:49:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258317, encodeId=c3a825831ee9, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 03 10:50:38 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258112, encodeId=558925811266, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Nov 02 19:24:43 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2018-05-22 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=1739802, encodeId=bb491e39802de, content=<a href='/topic/show?id=c318248e2f8' target=_blank style='color:#2F92EE;'>#人工血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24872, encryptionId=c318248e2f8, topicName=人工血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb434562879, createdName=thinkibmz_44722605, createdTime=Sat Jan 06 09:49:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656901, encodeId=659f165690168, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue May 22 15:49:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608197, encodeId=176d160819e00, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 04 07:49:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258317, encodeId=c3a825831ee9, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 03 10:50:38 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258112, encodeId=558925811266, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Nov 02 19:24:43 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1739802, encodeId=bb491e39802de, content=<a href='/topic/show?id=c318248e2f8' target=_blank style='color:#2F92EE;'>#人工血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24872, encryptionId=c318248e2f8, topicName=人工血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb434562879, createdName=thinkibmz_44722605, createdTime=Sat Jan 06 09:49:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656901, encodeId=659f165690168, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue May 22 15:49:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608197, encodeId=176d160819e00, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 04 07:49:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258317, encodeId=c3a825831ee9, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 03 10:50:38 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258112, encodeId=558925811266, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Nov 02 19:24:43 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-03 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1739802, encodeId=bb491e39802de, content=<a href='/topic/show?id=c318248e2f8' target=_blank style='color:#2F92EE;'>#人工血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24872, encryptionId=c318248e2f8, topicName=人工血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb434562879, createdName=thinkibmz_44722605, createdTime=Sat Jan 06 09:49:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656901, encodeId=659f165690168, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue May 22 15:49:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608197, encodeId=176d160819e00, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 04 07:49:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258317, encodeId=c3a825831ee9, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 03 10:50:38 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258112, encodeId=558925811266, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Nov 02 19:24:43 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-02 131****1460

    学习了受益匪浅.

    0

相关资讯

Diabetes Care:糖尿病患者CKD进展期血糖状态与糖尿病早期透析患者死亡率的关系如何?

在患有糖尿病的CKD过渡到透析的患者中,ESRD前期较高的平均HbA1c和随机血糖水平与较高的1年后ESRD死亡率相关。临床试验以评估调节血糖状态是否可以提高这类人群生存率是很有必要的。

JASN:透析的患者进行结肠癌筛查:选择是否明智?

结肠癌筛查是针对死亡风险最低和移植可能性最高的透析患者,但绝对率很高,提示存在过度筛查。

JACC:经导管主动脉瓣置换后的死亡和透析

在未调整和调整的分析中,术前GFR与死亡和新RRT结局相关。

Hypertension:动态脉搏波速度是血液透析患者心血管事件和全因死亡率的显著预测指标!

这些结果进一步支持动脉硬化是血液透析患者显著的心血管危险因素。

J Hypertens:透析患者用动态动脉硬度指数评估动脉硬化程度合适吗?

在血液透析患者中,AASI在评估动脉硬化程度上的价值有限,无论是单独使用或添加到PP。该研究结果表明,在今后的实践和研究中,该指标不应作为透析患者动脉硬化程度的评价指标。

Clin Oral Investig:肾脏疾病患者的口腔健康调查:一项从透析到肾移植的纵向研究

这篇研究的目的是为了比较患慢性肾脏疾病的患者透析(基线)和肾移植(进一步治疗)治疗阶段的口腔健康情况变化,并评估糖尿病肾病和其他肾脏疾病在追踪随访过程中的口腔健康差异。